| Prev Close | 35.25 |
| Day Low/High | 32.97 / 35.50 |
| 52 Wk Low/High | 9.00 / 56.50 |
Canopy Growth Corporation (CGC)
33.05
2.20
6.20
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 376.84B |
| Market Cap | 13.28B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: The Power of Memory to Make Money
Remember this: the market's often wrong.
Cronos Group Is Showing Us a Bullish Picture
Traders should look to buy available weakness into the $12-$11 area.
Canopy Growth Is Hot, and Here's How I'm Trading It
They really do not have very high hopes for the short to medium term future. Yet, the market buys their news.
Amazing Small-Caps, Minimum Wage, An Unhealthy Survey, Trading Nvidia, Chegg
The Russell 2000 has now soared 16% year to date, nearly twice the Nasdaq Composite's 8.5% move.
It's All (Cisco) Systems Go
CSCO is edging toward a major breakout level. Let's check the charts.
Things Are Heating Up for Canopy Growth: Our New Price Targets
Shares of the cannabis stock have recently strengthened.
Cannabis Leader Canopy Growth Can Climb Higher
Here's how to play CGC.
As the Focus on Psychedelic Stocks Increases, So Do the Valuations
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Democrat Wins Means Cannabis Wins
Georgia's election results have given the industry a big green light, meaning positive moves are expected out of cannabis stocks.
Constellation Brands Makes a Major Upside Breakout
Let's take a fresh look at the charts and indicators.
Canopy Growth Breaks Out on the Upside
Continue to hold longs in previous recommendations.
Georgia Contest Could Fire Up Cannabis Stocks
If Democrats score, marijuana names could benefit.
Tilray Wins, Even Though Aphria Is the Boss
Aphria investors will have a larger stake in the combined company post-merger.
MORE Act Passes, But It's Mostly Symbolic
This is the first time that any cannabis bill addressing descheduling has been approved by Congress.
With High Hopes, Hemp Looks Ahead to 2021
There were several reasons why the 2020 supply fell from 2019 levels.
The Canopy Growth Rally Catches a Second Wind
Traders could approach CGC from the long side.
Voters Spoke and the Winner Is Cannabis
A 'green wave' has advanced cannabis legalization across America. And that's just one of the forces powering up pot stocks right now.
The Clock Is Ticking for Cannabis SPACs
Collective Growth Corp is the first and largest SPAC focused on building the U.S. commercial hemp supply chain.
The Meaning of Biden, Overbought Markets? Fun With Charts
Can corporate America grow sales for the fourth quarter? Then answer a question with a question.
Taking Another Look at Canopy Growth
Let's review the charts of this cannabis firm to see if a sustained advance is ready to begin.
New York Lays the Groundwork for Legalizing Cannabis
The potential of legal New York adult-use cannabis sales have been estimated at $1.5 billion a year by 2023.
One Way or Another, Cannabis Is on the Election Ballot
Cannabis investors are keenly aware of the landscape and how it could play out for the industry.
3 Cannabis Stock Plays to Consider
Let's take a close look at Canopy Growth, GrowGeneration and cannabis REIT Innovative Industrial Properties.
What Were Those Analysts Smoking?
Just as we saw with pot stocks, if you play shares strictly because they're going up, you're likely to get burnt.
Among Cannabis Stocks, Here's a Breath of Fresh Ayr
Ayr Strategies is expanding in a contracting market.
Here's How to Make Sense of the Canopy Growth, Acreage Deal
The amended deal between the two cannabis companies is a doozy.
Just How Strong Are Constellation Brands' Charts?
I continue to recommend a reduced long exposure on STZ.
Investing in Cannabis? Don't 'Write Off' This Item
Publicly traded cannabis companies are expected to take big write downs on assets, and here's why it matters.
